德国使用拉那度单抗治疗遗传性血管性水肿的真实世界治疗模式：一项处方数据分析。 - Suppr

Suppr

超能文献

Real World treatment patterns of hereditary angioedema with lanadelumab in Germany: A prescription data analysis.

作者信息

Martinez-Saguer Inmaculada, Knop Jana, Flemming Amadeus, Thomann Michael, Maurer Marcus

机构信息

HZRM Hämophilie Zentrum Rhein Main, Mörfelden-Walldorf, Germany.

Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany.

出版信息

J Dtsch Dermatol Ges. 2022 Aug;20(8):1127-1129. doi: 10.1111/ddg.14785. Epub 2022 Aug 1.

DOI:10.1111/ddg.14785

PMID:35913113

Abstract

摘要

相似文献

Real World treatment patterns of hereditary angioedema with lanadelumab in Germany: A prescription data analysis.

J Dtsch Dermatol Ges. 2022 Aug;20(8):1127-1129. doi: 10.1111/ddg.14785. Epub 2022 Aug 1.

Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.

Allergy. 2023 May;78(5):1369-1371. doi: 10.1111/all.15620. Epub 2022 Dec 21.

Efficacy of lanadelumab in angioedema due to acquired C1 inhibitor deficiency.

J Allergy Clin Immunol Pract. 2023 Mar;11(3):963-965.e1. doi: 10.1016/j.jaip.2022.10.041. Epub 2022 Nov 13.

Efficacy of lanadelumab in acquired angioedema with C1-inhibitor deficiency.

J Allergy Clin Immunol Pract. 2021 Jun;9(6):2490-2491. doi: 10.1016/j.jaip.2021.01.040. Epub 2021 Feb 6.

Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation.

Ann Allergy Asthma Immunol. 2021 Sep;127(3):391-392. doi: 10.1016/j.anai.2021.05.028. Epub 2021 May 31.

Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study.

J Allergy Clin Immunol Pract. 2021 Oct;9(10):3744-3751. doi: 10.1016/j.jaip.2021.04.072. Epub 2021 May 20.

Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.

J Comp Eff Res. 2024 May;13(5):e230165. doi: 10.57264/cer-2023-0165. Epub 2024 Mar 28.

Lanadelumab (Takhzyro) for prevention of hereditary angioedema.

Med Lett Drugs Ther. 2021 Mar 8;63(1619):e41-e42.

Lanadelumab: First Global Approval.

Drugs. 2018 Oct;78(15):1633-1637. doi: 10.1007/s40265-018-0987-2.

Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy.

Drug Des Devel Ther. 2019 Oct 22;13:3635-3646. doi: 10.2147/DDDT.S192475. eCollection 2019.

引用本文的文献

Three-year real-world outcomes of lanadelumab prophylaxis in hereditary angioedema: Complete disease suppression and psychosocial benefits in two East Asian patients.

Intractable Rare Dis Res. 2025 Aug 31;14(3):210-215. doi: 10.5582/irdr.2025.01045.

Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study.

Adv Ther. 2025 Jun 12. doi: 10.1007/s12325-025-03226-3.

The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center.

Front Immunol. 2024 May 10;15:1405317. doi: 10.3389/fimmu.2024.1405317. eCollection 2024.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验